Volitionrx Ltd (VNRX) Stock Price, Quote & News

Company Profile

VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes; Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progre...

Industry: Medical Devices

Sector: Healthcare

Phone: 646 650 1351

Website: volition.com

Address:

1489 West Warm Springs Road, Suite 110, Henderson, United States

Iightning Nov. 22 at 2:20 AM

1ightning® Options Trade Alert (Actionable) | Buy $VNRX Dec 19 $2 Call | Enter: $0.31 Exit: $0.47 | Profit: 49.34% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 21 at 5:42 AM

1ightning® Options Trade Alert (Actionable) | Buy $VNRX Dec 19 $2 Call | Enter: $0.31 Exit: $0.47 | Profit: 49.34% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 20 at 3:38 AM

1ightning® Options Trade Alert (Actionable) | Buy $VNRX Dec 19 $2 Call | Enter: $0.31 Exit: $0.47 | Profit: 49.34% ROI | https://1ightning.com

0 · Reply

Kululu Nov. 19 at 9:31 PM

$VNRX no buying just selling

0 · Reply

Iightning Nov. 19 at 11:17 AM

1ightning® Options Trade Alert (Actionable) | Buy $VNRX Dec 19 $2 Call | Enter: $0.31 Exit: $0.47 | Profit: 49.34% ROI | https://1ightning.com

0 · Reply

2021er Nov. 18 at 8:54 PM

$VNRX stockprice doubled or almost from lows in the last two years a few times..i assume this run up will surpass the 0.7s and will hold up backed by werfen licensing and soon to come upfrontpayment for releasing their poster and felinetest

1 · Reply

CEOBuysDisclosures Nov. 17 at 8:15 PM

$VNRX CEO purchased 20,000 shares at $0.35 for a total of $7,000. Reynolds Cameron John now owns 3,596,641 shares. https://ceo-buys.com

1 · Reply

Kululu Nov. 17 at 6:19 PM

$VNRX these mf ceo is buying 20 k shares for 35 cent a piece. Such a loser guy. If you so sure about company why don’t you buy more shares.

3 · Reply

DARKP00L Nov. 17 at 1:30 PM

$VNRX 08:10 on Nov. 17 2025 D. Boral Capital Maintains Buy on VolitionRX, Maintains $5 Price Target #tradeideas

1 · Reply

JarvisFlow Nov. 17 at 1:10 PM

D. Boral Capital has adjusted their stance on VolitionRX ( $VNRX ), setting the rating to Buy with a target price of 5.

1 · Reply

VolitionRx Limited (VNRX) Q3 2025 Earnings Call Transcript

Nov 13, 2025, 4:10 PM EST - 10 days ago

VolitionRx Limited Announces Third Quarter 2025 Financial Results and Business Update

Nov 10, 2025, 8:45 AM EST - 13 days ago

VolitionRx Limited Schedules Third Quarter 2025 Earnings Conference Call and Business Update

Oct 17, 2025, 8:00 AM EDT - 5 weeks ago

Volition Donates Nu.Q® Vet Cancer Tests to HOPE Animal-Assisted Crisis Response Dogs

Oct 10, 2025, 8:30 AM EDT - 6 weeks ago

VolitionRx Limited Announces Pricing of $6.0 Million Underwritten Public Offering of Common Stock and Common Stock Warrants

Oct 9, 2025, 4:05 PM EDT - 6 weeks ago

VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock and Common Stock Warrants

Oct 8, 2025, 4:56 PM EDT - 6 weeks ago

VolitionRx Limited - Special Call

Oct 2, 2025, 8:45 AM EDT - 7 weeks ago

Volition Sponsors Upcoming GenomeWeb Webinar

Sep 29, 2025, 9:30 AM EDT - 7 weeks ago

Volition Signs Co-Marketing and Services Agreement with Hologic

HOLX

Sep 9, 2025, 8:45 AM EDT - 2 months ago

Volition Signs First Human Out Licensing Deal

Aug 15, 2025, 2:24 PM EDT - 3 months ago

VolitionRx Limited (VNRX) Q2 2025 Earnings Call Transcript

Aug 14, 2025, 4:10 PM EDT - 3 months ago

VolitionRx Limited Announces Second Quarter 2025 Financial Results and Business Update

Aug 8, 2025, 8:30 AM EDT - 3 months ago

VolitionRx Limited Schedules Second Quarter 2025 Earnings Conference Call and Business Update

Aug 4, 2025, 4:01 PM EDT - 3 months ago

VolitionRx Announces Pricing of $1.2 Million Registered Direct Offering

Jul 16, 2025, 8:00 AM EDT - 4 months ago

Nu.Q® Discover Expands Global Adoption and Epigenetic Innovation

Jul 8, 2025, 8:00 AM EDT - 4 months ago

Volition Announces Groundbreaking Lateral Flow Test for Point-of-Care Quantification of Nucleosomes

Jun 12, 2025, 8:30 AM EDT - 5 months ago

Volition Announces MARS Consortium Clinical Study Suggests Nu.Q® H3.1. Concentrations are Closely Associated with Sepsis and Organ Failure

Jun 4, 2025, 9:00 PM EDT - 6 months ago

Volition Announces Two Oral Presentations at Asian Meeting of Animal Medicine Specialties

May 19, 2025, 8:30 AM EDT - 6 months ago

VolitionRx Limited Announces Successful Detection of Nucleosomes in Cats

May 16, 2025, 7:19 PM EDT - 6 months ago

VolitionRX Limited (VNRX) Q1 2025 Earnings Call Transcript

May 15, 2025, 5:37 PM EDT - 6 months ago

VolitionRx Limited Announces First Quarter 2025 Financial Results and Business Update

May 12, 2025, 8:30 AM EDT - 6 months ago

VolitionRx Limited Schedules First Quarter 2025 Earnings Conference Call and Business Update

May 7, 2025, 8:30 AM EDT - 7 months ago

VolitionRX Limited: Outlines broad strategy to become the 'NETs company' worldwide through licensing and updates progress of Nu.Q® NETs test adoption

Apr 29, 2025, 8:30 AM EDT - 7 months ago

VolitionRX Limited: Revolutionizing the diagnosis and monitoring of life-altering diseases for both humans and animals in multi-billion dollar markets

Apr 1, 2025, 12:31 AM EDT - 8 months ago

VolitionRx Limited (VNRX) Q4 2024 Earnings Call Transcript

Mar 31, 2025, 4:05 PM EDT - 8 months ago

VolitionRx Limited Announces Full Fiscal Year 2024 Financial Results and Business Update

Mar 28, 2025, 8:00 AM EDT - 8 months ago

Volition Announces Two Poster Presentations at ESMO's European Lung Cancer Congress 2025

Mar 27, 2025, 8:30 AM EDT - 8 months ago

Volition to Host Virtual Investor Event on Nu.Q® Cancer, "A Look to the Future of Cancer Diagnostics", on April 9, 2025

Mar 26, 2025, 8:00 AM EDT - 8 months ago

VolitionRx Announces Pricing of up to $2.3 Million Registered Direct Offering

Mar 25, 2025, 9:30 AM EDT - 8 months ago

VolitionRx Limited Schedules Full Fiscal Year 2024 Earnings Conference Call and Business Update

Mar 21, 2025, 8:30 AM EDT - 8 months ago

Volition's Nu.Q® Cancer Diagnostics Test Aims To Disrupt the Multi-Billion Dollar Liquid Biopsy Industry

Mar 20, 2025, 8:30 AM EDT - 8 months ago

Volition Introduces Nu.Q® Cancer Blood Test in New Industry Primer for Lung Cancer

Mar 17, 2025, 8:30 AM EDT - 8 months ago

Volition Proudly Sponsors the 44th ISICEM Congress

Mar 13, 2025, 8:30 AM EDT - 9 months ago

Volition Signs first ever Nu.Q® Vet Cancer Test Automation Agreement with Fujifilm Vet Systems

Mar 11, 2025, 8:30 AM EDT - 9 months ago

Volition Announces First Patient Enrolled in NTU Hospital's Prospective Validation Study of Nu.Q® Lung Cancer Test

Mar 4, 2025, 8:30 AM EST - 9 months ago

Volition's Nu.Q® Discover Biomarkers to be utilized in Human Clinical Study Sponsored by Leading Pharmaceutical Company for the First Time

Feb 28, 2025, 8:30 AM EST - 9 months ago

Volition Showcases Nu.Q® Vet Cancer Test at the 97th WVC Annual Conference

Feb 6, 2025, 8:30 AM EST - 10 months ago

Volition Signs First Commercial Project Utilizing Rapid High-Throughput Model in the Study of NETosis

Feb 5, 2025, 9:15 AM EST - 10 months ago

Volition to Host Virtual Investor Event on Nu.Q® NETs, "Casting a New Light on Sepsis Management", on February 14, 2025

Jan 30, 2025, 8:30 AM EST - 10 months ago

Large clinical study establishes Nu.Q® NETs H3.1 as an independent predictor of 28-day mortality in sepsis

Jan 8, 2025, 8:30 AM EST - 11 months ago

Volition Issues Business Review 2024

Dec 12, 2024, 8:00 AM EST - 1 year ago

VolitionRx Appoints LifeSci Advisors as Investor Relations Consultants

Dec 10, 2024, 8:00 AM EST - 1 year ago

Study shows Nu.Q® Lung Cancer Test differentiated malignant and benign nodules found by Low Dose CT screening

Dec 6, 2024, 9:00 AM EST - 1 year ago

VolitionRx Announces Pricing of up to $1.9 Million Registered Direct Offering

Nov 15, 2024, 11:47 AM EST - 1 year ago

VolitionRx Limited (VNRX) Q3 2024 Earnings Call Transcript

Nov 14, 2024, 4:10 PM EST - 1 year ago

VolitionRx Limited Announces Third Quarter 2024 Financial Results and Business Update

Nov 8, 2024, 8:00 AM EST - 1 year ago

VolitionRx Limited Schedules Third Quarter 2024 Earnings Conference Call and Business Update

Nov 6, 2024, 4:10 PM EST - 1 year ago

Volition Appoints Timothy I. Still as Chairman

Oct 31, 2024, 8:00 AM EDT - 1 year ago

Multiple studies show Nu.Q® NETs test could predict sepsis patients at risk of deteriorating

Oct 9, 2024, 8:00 AM EDT - 1 year ago

Volition to share new 'NETs in sepsis management' data insights at upcoming webinar

Iightning Nov. 22 at 2:20 AM

1ightning® Options Trade Alert (Actionable) | Buy $VNRX Dec 19 $2 Call | Enter: $0.31 Exit: $0.47 | Profit: 49.34% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 21 at 5:42 AM

1ightning® Options Trade Alert (Actionable) | Buy $VNRX Dec 19 $2 Call | Enter: $0.31 Exit: $0.47 | Profit: 49.34% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 20 at 3:38 AM

1ightning® Options Trade Alert (Actionable) | Buy $VNRX Dec 19 $2 Call | Enter: $0.31 Exit: $0.47 | Profit: 49.34% ROI | https://1ightning.com

0 · Reply

Kululu Nov. 19 at 9:31 PM

$VNRX no buying just selling

0 · Reply

Iightning Nov. 19 at 11:17 AM

1ightning® Options Trade Alert (Actionable) | Buy $VNRX Dec 19 $2 Call | Enter: $0.31 Exit: $0.47 | Profit: 49.34% ROI | https://1ightning.com

0 · Reply

2021er Nov. 18 at 8:54 PM

1 · Reply

CEOBuysDisclosures Nov. 17 at 8:15 PM

$VNRX CEO purchased 20,000 shares at $0.35 for a total of $7,000. Reynolds Cameron John now owns 3,596,641 shares. https://ceo-buys.com

1 · Reply

Kululu Nov. 17 at 6:19 PM

$VNRX these mf ceo is buying 20 k shares for 35 cent a piece. Such a loser guy. If you so sure about company why don’t you buy more shares.

3 · Reply

DARKP00L Nov. 17 at 1:30 PM

$VNRX 08:10 on Nov. 17 2025 D. Boral Capital Maintains Buy on VolitionRX, Maintains $5 Price Target #tradeideas

1 · Reply

JarvisFlow Nov. 17 at 1:10 PM

D. Boral Capital has adjusted their stance on VolitionRX ( $VNRX ), setting the rating to Buy with a target price of 5.

1 · Reply

lejd5158 Nov. 17 at 12:48 PM

$VNRX Guess we know who was buying now.

1 · Reply

Kululu Nov. 14 at 5:50 PM

$VNRX how can this stock be so piss poor. It’s hard to digest. Th management have no worries about share prices. They are regurgitating the same old shit in all earnings call

0 · Reply

Kululu Nov. 13 at 3:52 PM

$VNRX this stock is just pure shit show. God knows what’s going to happen after earnings. How much dilution can be done? They keep doing offering every 2 months and makes amendment to those offering by diluting shares. It’s just bad

0 · Reply

Bigspydee040 Nov. 12 at 9:51 PM

$VNRX - how can more than a million shares get traded and no price action happens ? I am confused

1 · Reply

jetty323 Nov. 11 at 6:11 AM

$VNRX will be lucky to hold .30 Reynolds is on a role!! Can't wait to hear of all the exciting news he has to offer on CC this friday. He's busy as a beaver creating excuses for the current letdown; spinning hopes and dreams for the next offering. Can't wait

1 · Reply

Bigspydee040 Nov. 11 at 12:06 AM

$VNRX - more dilution and admendments -https://ir.stockpr.com/volition/sec-filings-email/content/0001477932-25-008019/vnrx_8ka.htm

0 · Reply

2021er Nov. 10 at 7:43 PM

$VNRX if they execute half of their promises then this is so undervalued..

1 · Reply

Kululu Nov. 8 at 7:25 PM

$VNRX mfers keep diluting the shares

1 · Reply

Kululu Nov. 7 at 7:59 PM

$VNRX people just come here to dump this shit stock.

0 · Reply

2021er Nov. 7 at 5:57 PM

$VNRX done buying, holding from now lets see where we at in 2026..q3 26..

1 · Reply

2021er Nov. 7 at 4:43 PM

$VNRX crucial levels here..🍿

0 · Reply

SkinnyDude911 Nov. 7 at 3:16 PM

$VNRX

1 · Reply

Market Cap	39.54M
Revenue (ttm)	1.23M
Net Income (ttm)	-26.97M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-2,192.68%
Debt to Equity Ratio	-0.21

Volume	555,000
Avg Vol	737,514
Day's Range	N/A - N/A
Shares Out	122.80M
Stochastic %K	15%
Beta	1.24
Analysts	Strong Sell
Price Target	$2.89